TICKERNERD
Menu
OGIOGIHealthcare · Drug Manufacturers - Specialty & Generic

OGI Stock Forecast: Organigram Global, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.05
−1.87% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$151.4M
Ticker Nerd rank
41 / 100
Median analyst target
—
Analysts covering
5
Revenue$105.8M+49.4% y/y
Operating income$5.3M
Net income$105.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.3%
1M
−14.6%
YTD
−37.5%
1Y
−36.7%
From 52W high
−50.2%
From 52W low
+20.6%
$0.87
$2.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OGI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organigram Global, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
83
Size
71
Growth
59
Volatility
51
Quality
43
Momentum
42
Value
39
Issuance
19
Accruals
13

Revisions (83): Analysts have, on balance, been raising their forecasts.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OGI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.80$1.00$1.20$1.40$1.60$1.80$2.00Oct 25Jan 26Apr 26Jul 26OGI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 July 2023StifelMaintainsBuy$1.25 → $4.00
11 May 2021CIBCUpgradeNeutral—
14 Apr 2021CIBCDowngradeUnderperformer$5.00 → $3.25
10 Mar 2021BMO CapitalDowngradeUnderperform—
9 Jan 2020Raymond JamesDowngradeMarket Perform—
12 Nov 2019BMO CapitalDowngradeMarket Perform—
11 Oct 2019JefferiesUpgradeBuy—
25 Feb 2019JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OGI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Organigram Global, Inc. returned −36.7% against +17.5% for the S&P 500, dividends included.

OGI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26OGIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OGI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+571.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

Organigram Global, Inc. (OGI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
13.5×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
49.4%

Higher than 86% of US stocks

Earnings growth (YoY)
49.4%

Higher than 74% of US stocks

Gross margin
39.2%

Higher than 48% of US stocks

Operating margin
5.0%

Higher than 55% of US stocks

Net margin
28.0%

Higher than 88% of US stocks

Returns & dividend
Return on equity
17.6%

Higher than 78% of US stocks

Return on assets
−0.6%

Higher than 41% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Organigram Global, Inc. (OGI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Organigram Global, Inc. has a market value of $151.4M and an enterprise value of $160.2M.

  • Revenue in the twelve months to 30 June 2026: $309.2M. The latest quarter grew 49.4% year on year.

  • Net income over the same four quarters: $86.6M, a 28.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$29.7M.

  • Shares outstanding: 141.0M.

  • Trailing P/E: 2.4×; forward P/E: 47.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Organigram Global, Inc. employs 1,139 people — $271K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

OGI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
OGIOrganigram Global, Inc.$151.4M
41
LFCRLifecore Biomedical, Inc.$154.4M
3
ADCTADC Therapeutics SA$132.5M
74
ORGOOrganogenesis Holdings, Inc.$189.1M
50
DERMJourney Medical Corp.$197.6M
65
BGMBGM Group Ltd.$110.6M
41
SIGASIGA Technologies, Inc.$217.1M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organigram Global, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGI news & analysis

Organigram Global to Host 2026 OG Investor Session

Business Wire · 2 Sept 2026neutral

Organigram Global Inc. announced details of its 2026 OG Investor Session. The company noted it has a new leadership team, completed its first full quarter with Sanity Group, and sharpened its strategy, and looks forward to updating stakeholders.

Why it matters — The investor session will provide Organigram stakeholders with updates on the company's new leadership, integration of Sanity Group, and its go-forward strategy.

Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure

Business Wire · 20 Aug 2026positive

Organigram Global announced an accelerated integration of Sanity Group GmbH under a unified global operating structure, aligning leadership, operations, and market development across the combined organization. The company appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer to support the integration.

Why it matters — OGI watchers would care because this milestone advances the company's global growth strategy and consolidates its leadership and operations following the Sanity Group acquisition.

Organigram Global Inc. (OGI:CA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of Organigram Global Inc.'s Q3 2026 earnings call. The item is a transcript of the company's quarterly earnings conference call.

Why it matters — OGI watchers can review management's full remarks and Q&A from the Q3 2026 earnings call to understand the quarter's results and outlook directly from company leadership.

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Zacks Investment Research · 11 Aug 2026negative

OrganiGram (OGI) reported a fiscal Q3 quarterly loss of $0.05 per share, wider than the Zacks Consensus Estimate of a $0.01 loss and worse than the $0.03 loss reported a year earlier. The headline indicates the company beat revenue estimates.

Why it matters — OGI watchers would note that the company's per-share loss widened beyond analyst expectations and compared unfavorably with the prior-year period, even as the headline suggests revenue outperformed estimates.

Organigram Global Q3 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Organigram Global reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, supported by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories.

Why it matters — OGI watchers would care because record revenue and adjusted EBITDA reflect the company's growth from international consolidation and stronger Canadian category performance.

FAQ

Frequently asked questions about OGI stock

Is OGI stock a buy right now?

Of the 5 analysts covering Organigram Global, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Organigram Global, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGI?

As at 12 Sept 2026, Organigram Global, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).

What is the OGI stock forecast for 2030?

No analyst covering Organigram Global, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGI are extrapolating price history, which says nothing about the business.

How has OGI stock performed over the past year?

Organigram Global, Inc. returned -36.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organigram Global, Inc. do?

Organigram Global Inc. is a cannabis company focused on the production and sale of cannabis and cannabis-derived products in Canada.

What is the latest news on OGI?

The most recent item we track (Business Wire, 2 Sept 2026): "Organigram Global to Host 2026 OG Investor Session". Organigram Global Inc. announced details of its 2026 OG Investor Session. The company noted it has a new leadership team, completed its first full quarter with Sanity Group, and sharpened its strategy, and looks forward to updating stakeholders.

Company

About Organigram Global, Inc.

Organigram Global Inc. is a cannabis company focused on the production and sale of cannabis and cannabis-derived products in Canada. The company serves both medical and adult-use recreational markets with a broad portfolio that includes whole flower, pre-rolls, vapes, beverages, gummies, concentrates, and other cannabis formats. Its product lineup is sold under well-known brands such as SHRED, Edison Cannabis Co., Big Bag O’ Buds, Monjour, Trailblazer, Boxhot, and DEBUNK. Organigram Global also participates in cannabinoid beverages and maintains a manufacturing and cultivation footprint across Canada to support indoor-grown cannabis production and product processing. Headquartered in Toronto, Ontario, the company is a licensed cultivator and manufacturer that plays a significant role in Canada’s regulated cannabis industry.

CEO Mr. James H. Yamanaka · 1,139 employees · Canada · https://www.organigram.ca